Clinical Efficacy Endpoints from the Phase 3 CANOPY Study Evaluating[...]
Pharmacokinetics and Serum Virus Neutralizing Antibody Titers Following[...]
Results from a Phase 1 First in human Study of Pemivibart: an[...]
04/21/2014 | Press release | Archived content
Please select the service you want to use:
Smartlinks | Hitachi Ltd. | Company News | Securities Issuers | Industrial Conglomerates | Frankfurt Stock Exchange | Vienna Stock Exchange (ATX) | Berlin Stock Exchange | Dusseldorf Stock Exchange | Munich Stock Exchange | Stuttgart Stock Exchange | Bolsa Mexicana de Valores (BMV) | Nagoya Stock Exchange (NSE) | OTC Markets | Tradegate Exchange | Tokyo Stock Exchange (TSE) | Chi-X Japan | Japan Securities Finance (JSF) | SBI Japannext | Bolsa Institucional de Valores (BIVA)
Copyright ©2006-2024 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact